PubMed Health⌕ Search

Biomedical subjects

H Duchková

Publications and source records attributed to H Duchková.

At least 19 recordsLinked to original sources
PubMed1998

[Immunomodulation in the treatment of atopic dermatitis].

In the submitted review the authors present information on possibilities of immunomodulating treatment of atopic dermatitis. Immunosuppressive treatment comprises systemic corticosteroid administration (possibly combined with cytostatic immunosuppressive preparations), cyclosporin A and phototherapy. Immunopotentiating treatment of AD makes use mainly of modulating preparations with the nature of physiological substances close to the immune system, substances obtained from natural biological sources (thymic hormones) or in recent years more frequently substances of recombinant origin (interferons, interleukins). The use of immunopotentiating drugs of chemical origin (synthetic substances) is used less frequently in AD. The use of intravenous immunoglobulin preparations for severe forms of atopic dermatitis is only just starting.

Adjuvants, Immunologic↗
PubMed1980

Urinary excretion of zinc and magnesium in malignant melanoma.

As zinc is the dominant trace element of melanin pigmentation, its urinary excretion was studied in 63 patients with malignant melanoma and also in groups of carcinoma patients and normal subjects. For comparison, magnesium excretion was also measured. As the melanoma progressed, the zinc excretion increased, but there was no correlation between the magnesium excretion and the stage of melanoma. There were no significant differences in excretion of either metal between the groups of treated melanoma patients, normal individuals, or the carcinoma patients.

Carcinoma↗
PubMed1979

Disseminated intravascular coagulation associated with toxic epidermal necrolysis (Lyell's syndrome).

Evidence of disseminated intravascular coagulation was recorded in eight patients with toxic epidermal necrolysis (TEN)--Lyell's syndrome. Patients were treated with low doses of heparin in combination with the usual treatment of TEN, i.e. maintenance of fluid and electrolyte balance, systemic corticosteroids, antibiotics and aseptic dressings, in the Intensive Care Unit environment. It is suggested that the alteration of haemostasis and inter-related biological systems, such as activation of components of complement, kinins and immunoglobulins, may affect the outcome of TEN.

Adult↗